Collplant biotechnologies reports 2025 second quarter financial results and provides corporate update

- sales of rhcollagen and bioinks primed for augmentation following new u.s.-based commercial executive hire - - raised $3.6 million in registered direct offering in second quarter -  rehovot, israel , aug. 20, 2025 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhcollagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter of 2025 and provided a corporate update. yehiel tal, collplant's chief executive officer commented, "in recent months, collplant has been making strong progress with its photocurable dermal and soft tissue filler program, completing additional testing and preparing for the clinical phase.
CLGN Ratings Summary
CLGN Quant Ranking